These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 20335218)

  • 1. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
    Quiroga MP; Balakrishnan K; Kurtova AV; Sivina M; Keating MJ; Wierda WG; Gandhi V; Burger JA
    Blood; 2009 Jul; 114(5):1029-37. PubMed ID: 19491390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
    Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
    Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
    Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
    Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
    Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
    Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
    Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
    Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
    Buchner M; Fuchs S; Prinz G; Pfeifer D; Bartholomé K; Burger M; Chevalier N; Vallat L; Timmer J; Gribben JG; Jumaa H; Veelken H; Dierks C; Zirlik K
    Cancer Res; 2009 Jul; 69(13):5424-32. PubMed ID: 19549911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
    McCaig AM; Cosimo E; Leach MT; Michie AM
    Br J Haematol; 2011 Apr; 153(2):199-211. PubMed ID: 21352196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia.
    Benkisser-Petersen M; Buchner M; Dörffel A; Dühren-von-Minden M; Claus R; Kläsener K; Leberecht K; Burger M; Dierks C; Jumaa H; Malavasi F; Reth M; Veelken H; Duyster J; Zirlik K
    PLoS One; 2016; 11(12):e0169159. PubMed ID: 28036404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
    Suljagic M; Longo PG; Bennardo S; Perlas E; Leone G; Laurenti L; Efremov DG
    Blood; 2010 Dec; 116(23):4894-905. PubMed ID: 20716772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
    Feng G; Wang X
    Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells.
    López-Guerra M; Xargay-Torrent S; Pérez-Galán P; Saborit-Villarroya I; Rosich L; Villamor N; Aymerich M; Roué G; Campo E; Montserrat E; Colomer D
    Leukemia; 2012 Jun; 26(6):1429-32. PubMed ID: 22182921
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
    de Rooij MF; Kuil A; Geest CR; Eldering E; Chang BY; Buggy JJ; Pals ST; Spaargaren M
    Blood; 2012 Mar; 119(11):2590-4. PubMed ID: 22279054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
    Bernard S; Danglade D; Gardano L; Laguillier C; Lazarian G; Roger C; Thieblemont C; Marzec J; Gribben J; Cymbalista F; Varin-Blank N; Ledoux D; Baran-Marszak F
    Int J Cancer; 2015 Jun; 136(12):2761-74. PubMed ID: 25388373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression of sphingosine-1 phosphate receptor-1 in chronic lymphocytic leukemia cells is impaired by tumor microenvironmental signals and enhanced by piceatannol and R406.
    Borge M; Remes Lenicov F; Nannini PR; de los Ríos Alicandú MM; Podaza E; Ceballos A; Fernández Grecco H; Cabrejo M; Bezares RF; Morande PE; Oppezzo P; Giordano M; Gamberale R
    J Immunol; 2014 Sep; 193(6):3165-74. PubMed ID: 25127862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Friedberg JW; Sharman J; Sweetenham J; Johnston PB; Vose JM; Lacasce A; Schaefer-Cutillo J; De Vos S; Sinha R; Leonard JP; Cripe LD; Gregory SA; Sterba MP; Lowe AM; Levy R; Shipp MA
    Blood; 2010 Apr; 115(13):2578-85. PubMed ID: 19965662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.
    Paiva C; Rowland TA; Sreekantham B; Godbersen C; Best SR; Kaur P; Loriaux MM; Spurgeon SEF; Danilova OV; Danilov AV
    Haematologica; 2017 Nov; 102(11):1890-1900. PubMed ID: 28838991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
    Longo PG; Laurenti L; Gobessi S; Sica S; Leone G; Efremov DG
    Blood; 2008 Jan; 111(2):846-55. PubMed ID: 17928528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.